Nuvation Bio (NUVB) Net Cash Flow (2020 - 2026)

Nuvation Bio (NUVB) has reported Net Cash Flow for 7 consecutive years, with -$38.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Cash Flow fell 418.29% year-over-year to -$38.5 million; the TTM figure through Mar 2026 stood at $78.0 million (up 506.41% YoY), while the FY2025 annual figure was $128.6 million, up 1843.16% from the prior year.
• Net Cash Flow slipped to -$38.5 million in Q1 2026 per NUVB's latest filing, from $65.4 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $200.1 million in Q2 2025 and bottomed at -$149.0 million in Q3 2025.
• Historically, Net Cash Flow has averaged -$414588.2 across 5 years, with a median of -$3.5 million in 2024.
• On a YoY basis, Net Cash Flow climbed as much as 66146.53% in 2025 and fell as far as 4149.07% in 2025.
• Nuvation Bio's Net Cash Flow stood at -$37.6 million in 2022, then soared by 148.56% to $18.3 million in 2023, then slumped by 74.96% to $4.6 million in 2024, then soared by 1331.49% to $65.4 million in 2025, then sank by 158.89% to -$38.5 million in 2026.
• Business Quant data shows NUVB's Net Cash Flow at -$38.5 million in Q1 2026, $65.4 million in Q4 2025, and -$149.0 million in Q3 2025.